ArticleInternational journal of clinical and experimental medicine2014
Leu125Val polymorphism of platelet endothelial cell adhesion molecule-1 is associated with atherosclerotic cerebral infarction in Chinese Han population.
Article in International journal of clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Involvement of TIMP-1 in PECAM-1-mediated tumor dissemination.International journal of oncology · 2018Article
- PECAM-1 Leu125Val (rs688) Polymorphism and Diabetic Nephropathy in Caucasians with Type 2 Diabetes Mellitus.Analytical cellular pathology (Amsterdam) · 2016Article
- Association of susceptibility to septic shock with platelet endothelial cell adhesion molecule-1 gene Leu125Val polymorphism and serum sPECAM-1 levels in sepsis patients.International journal of clinical and experimental medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A total of 142 Atherosclerotic cerebral infarction (ACI) patients and 116 controls were enrolled in our study. The Leu125Val polymorphism of PECAM-1 was genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The plasma sPECAM-1 level was measured by enzyme-linked immunosorbent assay (ELISA) method. We found a statistically significant difference in Leu125Val genotypic distribution between cases and controls (P < 0.05). The frequencies of the Val allele between ACI group and controls were significantly different (P < 0.05). Logistic regression analysis showed that the genotype Val/Val was associated with increased ACI risk (OR = 2.355, 95% CI = 1.153-4.809, P = 0.019). In both the ACI group and the control group, the plasma PECAM-1 levels of carriers of the Val/Val genotype were higher than those carrying Leu/Leu and Leu/Val genotypes. The plasma sPECAM-1 level is associated with ACI. Our study showed that Leu125Val polymorphism of PECAM-1 may be associated with ACI risk. Carrying the Val/Val genotype showed increased risk for ACI. The Leu125Val polymorphism of PECAM-1 may be associated with the plasma sPECAM-1 level, which is associated with Chinese ACI also. In conclusions, The Leu125Val polymorphism of the PECAM-1 gene is likely to be related to ACI, and the Val/Val genotype may be an independent risk factor for ACI. The plasma sPECAM-1 level may be associated with ACI risk.
Indexed as
Identifiers
25664111PMC4307558W2302659744What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.